Business Context and Reporting Period
This Form 8-K is filed by Medasorb Technologies Corporation (referred to in metadata as Cytosorbents Corp) for the reporting period of October 5, 2009. The filing reports on unregistered sales of equity securities and Regulation FD disclosures related to warrant exercises.
Key Financial Metrics
- Cash Proceeds: The Company received net cash proceeds of $1,307,132 from the exercise of warrants.
- Non-Cash Issuance: An additional $28,620 of Series B Convertible Preferred Shares were issued to attorneys in lieu of cash for legal fees.
- Equity Issued: Investors exercised warrants to purchase 13,357.52 shares of Series B Convertible Preferred stock at $100.00 per share.
- New Warrants Granted: Exercising investors received new warrants to purchase up to 12,483,664 shares of Common Stock at an exercise price of $0.107 per share.
The filing does not provide data on revenue, profit, operating margins, total debt, or liquidity ratios.
Material Changes
The primary material change is the capital raise resulting from the exercise of Series B Warrants. The Company voluntarily extended the expiration date of these warrants (originally set for September 25, 2009) to incentivize exercise. Warrants not exercised by October 5, 2009, have expired.
Outlook, Risks, and Unusual Items
Management Commentary: The transaction was structured as an incentive for warrantholders, offering additional common stock warrants upon exercise of the preferred stock warrants. The new common stock warrants expire one year after issuance.
Regulatory Status: The Company claims an exemption from registration requirements under Section 4(2) of the Securities Act and/or Regulation D, citing that the transaction did not involve a public offering and involved accredited investors.
Risks: The filing notes that the information contained herein is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly incorporated by reference.
Investor Verification Checklist
- Verify the exact number of shares of Series B Convertible Preferred stock issued versus the number of new Common Stock warrants granted.
- Confirm the current cash balance and liquidity position following the $1.3 million inflow.
- Review the terms of the new Common Stock warrants, specifically the $0.107 exercise price and one-year expiration.
- Check for any subsequent filings regarding the status of the unexercised Series B Warrants that expired.